NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

Calendar

06-23 - Significant Split/Dividend

More about the company

Income Statement and Estimates

More financial data

End-of-day quote Euronext Paris Other stock markets 05/02/2024			5-day change	1st Jan Change
1.980 ^EUR	-1.00%		-1.00%	-1.00%

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

Market Cap	4.15K 4.81K 3.82K 3.58K 6.73K 455K 6.8K 45.11K 17.58K 223K 18.05K 17.67K 772K	P/E Ratio 2023 *	-	P/E Ratio 2024	-
Enterprise Value	-201K -233K -185K -174K -326K -22.04M -330K -2.19M -852K -10.8M -875K -856K -37.41M	EV / Sales 2023	-	EV / Sales 2024	-0.12x
Free-Float	1.27%	Yield 2023 *	-	Yield 2024	-

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates
04/06/24	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

06-15	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
05-22	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
05-22	L'IA reprend le leadership
05-04	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
05-04	Coup de théâtre ou coup d'épée dans l'eau ?

NEOVACS Stock Euronext Paris

Stocks

ALNEV

FR001400HDX0

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile

Income Statement and Estimates

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	-1.00%	-1.00%	-	-	369K
LONZA GROUP AG	-0.12%	-0.18%	-12.80%	-12.90%	43.58B
REVOLUTION MEDICINES, INC.	-2.17%	+4.70%	+293.71%	+535.99%	34.03B
BEONE MEDICINES AG	-1.60%	-1.58%	-0.19%	+31.82%	29.82B
IQVIA HOLDINGS INC.	+0.44%	-3.80%	+12.51%	-17.06%	29.77B
CELLTRION, INC.	-0.29%	+2.65%	+13.24%	+21.04%	25.42B
ASCENDIS PHARMA A/S	+3.54%	+8.43%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-1.26%	-1.11%	+53.37%	+108.10%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.48%	+2.42%	+1.98%	12.85B
IONIS PHARMACEUTICALS, INC.	-1.18%	-2.00%	+107.41%	+78.18%	12.22B
Average	-0.47%	+1.20%	+58.71%	+93.39%	23.88B
Weighted average by Cap.	-0.54%	+1.22%	+60.66%	+104.83%

	2023	2024
Net sales	533K 619K 491K 461K 866K 58.52M 875K 5.8M 2.26M 28.66M 2.32M 2.27M 99.31M	434K 504K 400K 375K 704K 47.61M 712K 4.72M 1.84M 23.31M 1.89M 1.85M 80.79M
Net income	-8.74M -10.15M -8.05M -7.56M -14.19M -959M -14.34M -95.14M -37.06M -470M -38.08M -37.27M -1.63B	-32.91M -38.19M -30.31M -28.46M -53.43M -3.61B -53.99M -358M -140M -1.77B -143M -140M -6.13B
Net Debt	-237K -274K -218K -204K -384K -25.95M -388K -2.57M -1M -12.71M -1.03M -1.01M -44.03M	-205K -238K -189K -177K -333K -22.5M -336K -2.23M -869K -11.02M -893K -874K -38.18M